Skip to main content
OpenTrials
Completed

NCT Number: NCT05195216

Psychosocial Factors and Quality of Life in the Effect of Fear of COVID-19 With Cystic Fibrosis

The purpose of this study; The COVID-19 pandemic is to investigate the effects of COVID-19 fear levels of patients with cystic fibrosis on the psychosocial and quality of life levels of individuals.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Elif Kabasakal

Istanbul, İ̇stanbul, 34734, Turkey (Türkiye)

About this study

After individuals were informed about the study, it was administered to individuals who gave written informed consent.This study was carried out on individuals with cystic fibrosis and healthy individuals who meet the eligibility requirements, through online forms.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • be 16 years of age or older
  • Having been diagnosed with Cystic Fibrosis
  • Volunteering to participate in the research

Exclusion criteria

  • Being mentally incapable of successfully applying the scales to be applied for evaluation purposes
  • Being treated with sedative and antiepileptic drugs
  • Pregnancy

Treatment and study plan

Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form

Behavioral

Online questionnaires were administered to individuals.

Primary outcomes

  1. fear of covid-19

    Time frame: November- December/2021

    COVID-19 Fear Scale: This scale is a one-dimensional instrument consisting of seven items with robust psychometric properties that measure fear of COVID-19. It has a 5-point Likert-type rating system (1: Strongly disagree, 5: Strongly agree). It is reliable and valid in assessing fear of COVID-19 among the general population. Turkish validity and reliability of the scale were ensured.

Secondary outcomes

  1. psychosocial factors

    Time frame: November-December/2021November-December/2021

    Hospital Anxiety and Depression Scale (HADS): The scale consists of 14 items. 7 of these items measure anxiety and 7 of them measure depression symptoms. The items in the scale are evaluated with a 4-point Likert scale and are based on a scoring system between 0-3.

Other outcomes

  1. quality of life assessment

    Time frame: November-December/2021November-December/2021

    It is an internationally comparable assessment tool developed by the World Health Organization. The scale evaluates the level of quality of life. The scale consists of 26 items. The Turkish version of WHOQOL-Bref consists of 27 items. Question 27 has been added to the Turkish version of the scale as a national environmental field and is used only in national studies. The scale includes the areas of physical health, psychological health, social relations, environment and national environment. It has a 5-point likert-type rating system. The score of each area is important on its own. Higher scores in each area indicate better quality of life. The first two questions of the quality of life scale are not included in the scoring and are evaluated separately. The number of questions, which was 26 in the original of the scale, is used as 27 in the Turkish version.

Sponsors and collaborators

Lead sponsor

Elif Kabasakal

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jan 18, 2022
Registry last updated
Jan 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.